Further modifications of the treatment protocol with regards to the use of adjuvant radiosensitizers and dynamic escalation of 225Ac-PSMA-617 therapy dosage to 150 or 200 KBq/Kg BW may be the alternative options in these set of patients an initial tumor response to treatment, to achieve best disease control rate with minimal toxicity. The gene discussed is FOLH1; the disease is neoplasm.